What is Micofenolato Mofetile used for?

Micofenolato Mofetile Aurobindo

Active Ingredient:: Mycophenolate Mofetil
Origin:: EU

Micofenolato Mofetile Aurobindo (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Micofenolato Mofetile, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent acute rejection in solid‑organ transplantation and to treat lupus nephritis and other autoimmune conditions where immune suppression is required.

GNH India supplies Micofenolato Mofetile as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution, including batch release certificates and stability data.

Manufacturer / TM Owner

Aurobindo Pharma (Italia) S.R.L.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Mycophenolate Mofetil is used to suppress immune responses in several transplant and autoimmune contexts.

Kidney transplantation: helps prevent acute graft rejection.
Heart transplantation: reduces incidence of rejection episodes.
Liver transplantation: supports maintenance immunosuppression.
Lupus nephritis: contributes to disease control and renal protection.
Other solid organ transplants: provides long‑term immunosuppression.

How It Works

Mycophenolate Mofetil selectively inhibits inosine monophosphate dehydrogenase (IMPDH), the enzyme responsible for de novo synthesis of guanosine nucleotides in lymphocytes. By depleting guanosine pools, it blocks proliferation of T and B cells, thereby attenuating the cellular and humoral immune response essential for graft rejection and autoimmunity. The inhibition is reversible and preferentially affects activated lymphocytes while sparing most other cell types, leading to a targeted immunosuppressive effect.

Side Effects

Mycophenolate Mofetil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain.
Infections: increased susceptibility to bacterial, viral or fungal infections.
Hematologic changes: anemia, leukopenia or thrombocytopenia.
Headache: mild to moderate intensity.

Serious or Rare Side Effects

Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia.
Malignancy: increased risk of lymphoproliferative disorders or skin cancers.
Hepatotoxicity: elevated liver enzymes or hepatitis.
Bone marrow failure: aplastic anemia or pancytopenia.

Precautions & Warnings

When prescribing Mycophenolate Mofetil, clinicians should consider several precautionary measures to minimize risk.

Pregnancy: contraindicated; teratogenic risk requires effective contraception.
Renal impairment: dose adjustment may be needed; monitor renal function.
Hepatic impairment: use with caution; monitor liver enzymes.
Infection risk: screen for latent infections and vaccinate before therapy.
Blood monitoring: regular complete blood counts to detect cytopenias.
Store at ambient temperature: keep below 25 °C, in original container, protect from moisture.

Avoid Interactions

Mycophenolate Mofetil interacts with several agents that can alter its efficacy or safety profile.

Major Interactions (Avoid)

Antimetabolites (e.g., azathioprine): additive bone marrow suppression.
Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce drug exposure.
Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours.
ACE inhibitors or ARBs: may exacerbate renal dysfunction; monitor kidney function.
Vaccines (inactivated): generally safe but monitor immune response.

Frequently Asked Questions

Micofenolato Mofetile contains Mycophenolate Mofetil, an immunosuppressant used to prevent acute rejection after solid‑organ transplantation (such as kidney, heart or liver) and to treat autoimmune

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 09 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.